savolitinib

• 

Savolitinib and durvalumab for metastatic papillary kidney cancer

By Sharon Deveson Kell|2023-03-23T09:27:27+00:0023 Mar 2023|Drug treatments|

In a phase 2 clinical trial, patients with metastatic papillary [...]

Read More

Comments Off on Savolitinib and durvalumab for metastatic papillary kidney cancer

• 

Savolitinib plus durvalumab for papillary kidney cancer

By Sharon Deveson Kell|2023-03-06T12:34:35+00:006 Mar 2023|Drug treatments|

In a recent study published in the Journal of Clinical [...]

Read More

Comments Off on Savolitinib plus durvalumab for papillary kidney cancer

• 

Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

By Sharon Deveson Kell|2022-06-08T10:28:09+00:008 Jun 2022|Drug treatments|

At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]

Read More

Comments Off on Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

• 

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

By Sharon Kell|2021-02-15T10:03:32+00:0015 Feb 2021|Drug treatments|

A gene called MET codes for a protein called MET [...]

Read More

Comments Off on ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

• 

ASCO 2020: Savolitinib is promising for the treatment of papillary renal cell carcinoma

By Sharon Kell|2020-06-01T09:24:52+00:001 Jun 2020|Uncategorized|

In a study presented during the 2020 American Society of [...]

Read More

Comments Off on ASCO 2020: Savolitinib is promising for the treatment of papillary renal cell carcinoma

• 

ASCO GU 2020: Overall survival results for savolitinib and durvalumab in papillary kidney cancer

By Sharon Kell|2020-02-21T15:05:41+00:0021 Feb 2020|Drug treatments|

Overall survival results from a study with a combination of [...]

Read More

Comments Off on ASCO GU 2020: Overall survival results for savolitinib and durvalumab in papillary kidney cancer

• 

Savolitinib shows promise in first-in-human phase 1 study in solid tumours

By Sharon Kell|2019-05-07T13:50:24+00:007 May 2019|Drug treatments|

Results from a first-in-human phase 1 study of savolitinib in [...]

Read More

Comments Off on Savolitinib shows promise in first-in-human phase 1 study in solid tumours

• 

ASCO GU 2019: Savolitinib and durvalumab in metastatic papillary kidney cancer

By Sharon Kell|2019-02-26T12:31:40+00:0026 Feb 2019|Drug treatments|

Results from this trial for papillary renal cell carcinoma (RCC) [...]

Read More

Comments Off on ASCO GU 2019: Savolitinib and durvalumab in metastatic papillary kidney cancer

Current treatment of advanced papillary renal cell carcinoma

By Sharon Kell|2017-07-26T07:43:03+00:0026 Jul 2017|Drug treatments|

Despite significant improvements in the treatment outcomes of clear cell [...]

Read More

Comments Off on Current treatment of advanced papillary renal cell carcinoma

Chi-Med and AstraZeneca initiate global phase III clinical trial of savolitinib in papillary kidney cancer (SAVOIR)

By Sharon Kell|2017-06-29T15:50:44+00:0029 Jun 2017|Drug treatments|

Chi-Med (Hutchinson Pharma), a Hong Kong-based biotechnology company, and AstraZeneca [...]

Read More

Comments Off on Chi-Med and AstraZeneca initiate global phase III clinical trial of savolitinib in papillary kidney cancer (SAVOIR)